 The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force behind this resurgence.
After hitting a historic low in 2025—only eight biotechs went public, as per a BioSpace tally, the lowest in the post-pandemic era—initial public offerings (IPOs) seem to be on the upswing this year. And while the reasons for this resurgence are many, experts pointed to one largely underappreciated driver of this rebound: the rise of AI. 
Content mobilized by FeedBlitz RSS Services, the premium FeedBurner alternative. |
